Cholangiocarcinoma Clinical Trials in Houston, Texas
16 recruitingHouston, Texas
Showing 1–16 of 16 trials
Recruiting
Phase 2
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Resectable Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)27 enrolled58 locationsNCT06050252
Recruiting
Phase 1
A Study of PHST001 in Advanced Solid Tumors
Ovarian CancerEndometrial CancerCholangiocarcinoma+2 more
Pheast Therapeutics272 enrolled20 locationsNCT06840886
Recruiting
Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled28 locationsNCT07213791
Recruiting
Molecular Epidemiology of Biliary Tree Cancers
CholangiocarcinomaMalignant Digestive System Neoplasm
M.D. Anderson Cancer Center1,500 enrolled1 locationNCT05179486
Recruiting
Phase 2
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma
M.D. Anderson Cancer Center24 enrolled1 locationNCT05967182
Recruiting
Phase 2
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center60 enrolled1 locationNCT06858735
Recruiting
Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
CholangiocarcinomaBenign Liver TumorAdult Hepatocellular Carcinoma+2 more
M.D. Anderson Cancer Center110 enrolled1 locationNCT02379377
Recruiting
Phase 1
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Ovarian CancerMesothelioma, MalignantCholangiocarcinoma Recurrent
Verismo Therapeutics42 enrolled4 locationsNCT05568680
Recruiting
Phase 1Phase 2
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Cholangiocarcinoma
Genfit74 enrolled11 locationsNCT05874414
Recruiting
Phase 1Phase 2
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
Advanced CholangiocarcinomaFGFR2 Fusion
M.D. Anderson Cancer Center25 enrolled1 locationNCT06439485
Recruiting
Phase 1Phase 2
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Institut de Recherches Internationales Servier52 enrolled37 locationsNCT06501625
Recruiting
Phase 2
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
Taiho Oncology, Inc.120 enrolled65 locationsNCT05727176
Recruiting
Not Applicable
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
Pancreatic CancerMelanomaLiver Malignant Tumors+1 more
M.D. Anderson Cancer Center60 enrolled1 locationNCT05053555
Recruiting
Phase 1Phase 2
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316
Recruiting
Phase 1
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Solid TumorIntrahepatic CholangiocarcinomaLocally Advanced Cholangiocarcinoma+1 more
Tyra Biosciences, Inc40 enrolled4 locationsNCT06160752
Recruiting
Phase 3
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.200 enrolled87 locationsNCT05948475